Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

NCT07092410 is registered in ClinicalTrials.gov with SRH Wald-Klinikum Gera GmbH as lead sponsor.

NCT NCT07092410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07092410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib
Lead sponsor
SRH Wald-Klinikum Gera GmbH
Phase
Phase 4
Overall status
Withdrawn
Start date
August 31, 2025
Completion date
August 31, 2030
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma braf v600e/k mutated